Versatope Therapeutics, Inc.
Publicly observedLowell, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Lowell | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Versatope Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | VSMPM3EGYYA6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant8 Dec 2023Publicly observed
NIH SBIR/STTR award: Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine
USD 999,925.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant8 Dec 2023Publicly observed
NIH SBIR/STTR award: Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine
USD 999,993.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.